Cost Insights: Breaking Down GSK plc and Alkermes plc's Expenses

GSK vs. Alkermes: A Decade of Cost Evolution

__timestamp	Alkermes plc	GSK plc
Wednesday, January 1, 2014	447875000	7323000000
Thursday, January 1, 2015	483393000	8853000000
Friday, January 1, 2016	519270000	9290000000
Sunday, January 1, 2017	567637000	10342000000
Monday, January 1, 2018	601826000	10241000000
Tuesday, January 1, 2019	693218000	11863000000
Wednesday, January 1, 2020	572904000	11704000000
Friday, January 1, 2021	603913000	11603000000
Saturday, January 1, 2022	218108000	9554000000
Sunday, January 1, 2023	253037000	8565000000
Monday, January 1, 2024	245331000

Infusing magic into the data realm

Unveiling Cost Dynamics: GSK plc vs. Alkermes plc

In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. From 2014 to 2023, GSK plc and Alkermes plc have showcased intriguing cost trends. GSK plc, a global healthcare giant, consistently reported higher costs, peaking in 2019 with a 62% increase from 2014. Meanwhile, Alkermes plc, a biopharmaceutical innovator, saw its costs rise by 55% during the same period, with a notable dip in 2022. This divergence highlights GSK's expansive operations compared to Alkermes' focused approach. The data reveals a 20% reduction in GSK's costs from 2019 to 2023, reflecting strategic cost management. Conversely, Alkermes experienced a 64% drop in 2022, possibly due to operational shifts. These insights underscore the importance of cost efficiency in sustaining competitive advantage in the pharmaceutical sector.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025